GlassScriptPhysician profile
Jawad H Khan
NPI 1407865082
$4,514.28
in general payments reported to CMS, 2019-2025
25 companies · $22.48 in 2025
The $22.48 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $112 · 2021: $610 · 2022: $1,242 · 2023: $1,930 · 2024: $385 · 2025: $22.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,337.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $774.10 | 2019-2024 | Breztri, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $645.75 | 2019-2024 | Trelegy Ellipta, Arexvy, Nucala |
| Regeneron Healthcare Solutions, INC. | $636.20 | 2021-2024 | Dupixent |
| Genzyme Corporation | $417.62 | 2019-2024 | |
| Mylan Specialty L.P. | $358.53 | 2019-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $264.78 | 2021-2023 | Glassia |
| Amgen INC. | $235.53 | 2022-2024 | Tezspire, Tavneos |
| Janssen Pharmaceuticals, INC | $162.73 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.78 | 2019-2023 | Ofev |
| Mallinckrodt Hospital Products INC. | $123.17 | 2021-2024 | Acthar |
| Electromed, INC. | $117.01 | 2019-2023 | Smartvest |
| Actelion Pharmaceuticals US, INC. | $115.59 | 2022-2023 | Uptravi, Opsumit |
| United Therapeutics Corporation | $103.37 | 2021-2023 | Tyvaso |
| Harmony Biosciences LLC | $82.18 | 2022-2023 | Wakix |
| Sanofi-Aventis U.S. LLC | $74.75 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $46.71 | 2023 | Keytruda, Belsomra |
| Philips North America LLC | $45.66 | 2022 | |
| Inspire Medical Systems, INC. | $40.09 | 2024-2025 | Inspire |
| Pulmonx Corporation | $23.46 | 2022 | |
| Novo Nordisk INC | $19.04 | 2023 | Wegovy |
| Idorsia Pharmaceuticals US INC | $17.79 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $14.83 | 2021 | |
| Jazz Pharmaceuticals INC. | $14.46 | 2019 | |
| Grifols USA, LLC | $14.15 | 2024 | Prolastin-C Liquid |
| Shire North American Group INC | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jawad Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.